CY1119992T1 - Παραγωγα πουρινης για χρηση στη θεραπευτικη αγωγη αλλεργικων, φλεγμονωδων και λοιμωδων ασθενειων - Google Patents
Παραγωγα πουρινης για χρηση στη θεραπευτικη αγωγη αλλεργικων, φλεγμονωδων και λοιμωδων ασθενειωνInfo
- Publication number
- CY1119992T1 CY1119992T1 CY20181100258T CY181100258T CY1119992T1 CY 1119992 T1 CY1119992 T1 CY 1119992T1 CY 20181100258 T CY20181100258 T CY 20181100258T CY 181100258 T CY181100258 T CY 181100258T CY 1119992 T1 CY1119992 T1 CY 1119992T1
- Authority
- CY
- Cyprus
- Prior art keywords
- allergic
- infectious diseases
- inflammatory
- purini
- products
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/18—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 one oxygen and one nitrogen atom, e.g. guanine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0043—Nose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/16—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two nitrogen atoms
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Engineering & Computer Science (AREA)
- Rheumatology (AREA)
- Otolaryngology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
Ενώσεις του τύπου (Ι) όπου το R1 είναι C1-6αλκυλαμινο, C1-6αλκοξυ, ή C3-7κυκλοαλκυλοξυ, το m είναι ένας ακέραιος που έχει μια τιμή 3 έως 6, το n είναι ένας ακέραιος που έχει μια τιμή 0 έως 4, και άλατα αυτών είναι επαγωγείς ανθρώπινης ιντερφερόνης. Ενώσεις οι οποίες επάγουν ανθρώπινη ιντερφερόνη μπορεί να είναι χρήσιμες στη θεραπευτική αγωγή διαφόρων διαταραχών, για παράδειγμα στη θεραπευτική αγωγή αλλεργικών ασθενειών και άλλων φλεγμονωδών καταστάσεων για παράδειγμα αλλεργικής ρινίτιδας και άσθματος, στη θεραπευτική αγωγή λοιμωδών ασθενειών και καρκίνου, και μπορεί επίσης να είναι χρήσιμες ως ανοσοενισχυτικά εμβολίων.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US8777708P | 2008-08-11 | 2008-08-11 | |
EP09781606.0A EP2324026B1 (en) | 2008-08-11 | 2009-08-07 | Purine derivatives for use in the treatment of allergic, inflammatory and infectious diseases |
Publications (1)
Publication Number | Publication Date |
---|---|
CY1119992T1 true CY1119992T1 (el) | 2018-12-12 |
Family
ID=41187189
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CY20181100258T CY1119992T1 (el) | 2008-08-11 | 2018-02-28 | Παραγωγα πουρινης για χρηση στη θεραπευτικη αγωγη αλλεργικων, φλεγμονωδων και λοιμωδων ασθενειων |
Country Status (38)
Country | Link |
---|---|
US (7) | US8067426B2 (el) |
EP (3) | EP2324026B1 (el) |
JP (1) | JP5529867B2 (el) |
KR (1) | KR101669939B1 (el) |
CN (2) | CN102177159B (el) |
AU (1) | AU2009281197B2 (el) |
BR (1) | BRPI0917138A2 (el) |
CA (1) | CA2733749C (el) |
CL (1) | CL2011000301A1 (el) |
CO (1) | CO6351791A2 (el) |
CR (1) | CR20110116A (el) |
CY (1) | CY1119992T1 (el) |
DK (2) | DK2324026T3 (el) |
DO (1) | DOP2011000048A (el) |
EA (1) | EA020631B1 (el) |
ES (2) | ES2661671T3 (el) |
HK (3) | HK1157770A1 (el) |
HR (2) | HRP20150938T1 (el) |
HU (2) | HUE036570T2 (el) |
IL (1) | IL210757A (el) |
LT (1) | LT3000813T (el) |
MA (1) | MA32624B1 (el) |
ME (1) | ME02274B (el) |
MX (2) | MX2011001666A (el) |
MY (1) | MY162538A (el) |
NO (1) | NO3000813T3 (el) |
NZ (2) | NZ602812A (el) |
PE (1) | PE20110674A1 (el) |
PL (2) | PL3000813T3 (el) |
PT (2) | PT3000813T (el) |
RS (2) | RS56984B1 (el) |
SG (1) | SG192547A1 (el) |
SI (2) | SI2324026T1 (el) |
SM (1) | SMT201500224B (el) |
TR (1) | TR201802648T4 (el) |
UA (1) | UA103195C2 (el) |
WO (1) | WO2010018133A1 (el) |
ZA (1) | ZA201100845B (el) |
Families Citing this family (62)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BRPI0509258A8 (pt) * | 2004-03-26 | 2019-01-22 | Astrazeneca Ab | composto de 8-oxoadenina 9-substituída |
EP1874772A1 (en) * | 2005-04-05 | 2008-01-09 | Pharmacopeia, Inc. | Purine and imidazopyridine derivatives for immunosuppression |
WO2007034817A1 (ja) * | 2005-09-22 | 2007-03-29 | Dainippon Sumitomo Pharma Co., Ltd. | 新規アデニン化合物 |
WO2008004948A1 (en) * | 2006-07-05 | 2008-01-10 | Astrazeneca Ab | 8-oxoadenine derivatives acting as modulators of tlr7 |
TW200831105A (en) * | 2006-12-14 | 2008-08-01 | Astrazeneca Ab | Novel compounds |
TW200843779A (en) * | 2007-02-19 | 2008-11-16 | Smithkline Beecham Corp | Compounds |
US8067413B2 (en) * | 2007-03-19 | 2011-11-29 | Astrazeneca Ab | 9-substituted-8-oxo-adenine compounds as toll-like receptor (TLR7 ) modulators |
ATE530549T1 (de) * | 2007-03-19 | 2011-11-15 | Astrazeneca Ab | 9-substituierte 8-oxoadeninverbindungen als modulatoren des toll-like-receptor (tlr7) |
AR065784A1 (es) * | 2007-03-20 | 2009-07-01 | Dainippon Sumitomo Pharma Co | Derivados de 8-oxo adenina,medicamentos que los contienen y usos como agentes terapeuticos para enfermedades alergicas, antivirales o antibacterianas. |
WO2008114819A1 (ja) * | 2007-03-20 | 2008-09-25 | Dainippon Sumitomo Pharma Co., Ltd. | 新規アデニン化合物 |
EP2155743B1 (en) * | 2007-05-08 | 2012-08-29 | AstraZeneca AB | Imidazoquinolines with immuno-modulating properties |
PT2170888E (pt) * | 2007-06-29 | 2015-08-21 | Gilead Sciences Inc | Purina derivados e sua utilização como moduladores de recetor de tipo toll 7 |
UY31531A1 (es) | 2007-12-17 | 2009-08-03 | Sales derivadas de 8-oxoadenina composiciones farmacéuticas que las contienen y su uso en terapia como moduladores de receptor tipo toll (tlr) | |
JPWO2009091031A1 (ja) * | 2008-01-17 | 2011-05-26 | 大日本住友製薬株式会社 | アデニン化合物の製造方法 |
EP2246353A4 (en) | 2008-01-17 | 2011-04-20 | Dainippon Sumitomo Pharma Co | PROCESS FOR PREPARING AN ADENINE COMPOUND |
US8802684B2 (en) | 2008-08-11 | 2014-08-12 | Glaxosmithkline Llc | Adenine derivatives |
WO2010018130A1 (en) | 2008-08-11 | 2010-02-18 | Smithkline Beecham Corporation | Purine derivatives for use in the treatment of allergic, inflammatory and infectious diseases |
PT2320905T (pt) | 2008-08-11 | 2017-09-19 | Glaxosmithkline Llc | Novos derivados de adenina |
UA103195C2 (uk) | 2008-08-11 | 2013-09-25 | Глаксосмитклайн Ллк | Похідні пурину для застосування у лікуванні алергій, запальних та інфекційних захворювань |
CN102272134B (zh) | 2008-12-09 | 2013-10-16 | 吉里德科学公司 | Toll样受体调节剂 |
CN102481376B (zh) | 2009-05-27 | 2016-12-21 | 西莱克塔生物科技公司 | 免疫调节剂-聚合物化合物 |
WO2011049825A1 (en) | 2009-10-22 | 2011-04-28 | Gilead Sciences, Inc. | Derivatives of purine or deazapurine useful for the treatment of (inter alia) viral infections |
WO2011068233A1 (en) * | 2009-12-03 | 2011-06-09 | Dainippon Sumitomo Pharma Co., Ltd. | Imidazoquinolines which act via toll - like receptors (tlr) |
US20110150836A1 (en) * | 2009-12-22 | 2011-06-23 | Gilead Sciences, Inc. | Methods of treating hbv and hcv infection |
US8575340B2 (en) | 2010-02-10 | 2013-11-05 | Glaxosmithkline Llc | Purine derivatives and their pharmaceutical uses |
CN102753553B (zh) * | 2010-02-10 | 2016-03-30 | 葛兰素史密丝克莱恩有限责任公司 | 6-氨基-2-{[(1s)-1-甲基丁基]氧基}-9-[5-(1-哌啶基)-7,9-二氢-8h-嘌呤-8-酮马来酸盐 |
AU2011258156B2 (en) | 2010-05-26 | 2016-11-24 | Selecta Biosciences, Inc. | Multivalent synthetic nanocarrier vaccines |
EP2640190A4 (en) | 2010-11-05 | 2016-05-11 | Selecta Biosciences Inc | MODIFIED NICOTINIC COMPOUNDS AND ASSOCIATED METHODS |
ES2575688T3 (es) | 2010-12-16 | 2016-06-30 | Sumitomo Dainippon Pharma Co., Ltd. | Derivado de imidazo[4,5-c]quinolin-1-ilo útil en terapia |
JP5978226B2 (ja) | 2010-12-17 | 2016-08-24 | 大日本住友製薬株式会社 | プリン誘導体 |
US9289477B2 (en) | 2011-04-29 | 2016-03-22 | Selecta Biosciences, Inc. | Tolerogenic synthetic nanocarriers to reduce cytotoxic T lymphocyte responses |
LT2734186T (lt) * | 2011-07-22 | 2018-12-10 | Glaxosmithkline Llc | Kompozicija |
WO2013019658A2 (en) | 2011-07-29 | 2013-02-07 | Selecta Biosciences, Inc. | Synthetic nanocarriers comprising polymers comprising multiple immunomodulatory agents |
GB201119999D0 (en) | 2011-11-20 | 2012-01-04 | Glaxosmithkline Biolog Sa | Vaccine |
GB201120000D0 (en) | 2011-11-20 | 2012-01-04 | Glaxosmithkline Biolog Sa | Vaccine |
EP2674170B1 (en) | 2012-06-15 | 2014-11-19 | Invivogen | Novel compositions of TLR7 and/or TLR8 agonists conjugated to lipids |
UY34987A (es) * | 2012-08-24 | 2014-03-31 | Glaxosmithkline Llc | ?nuevos compuestos inductores del interferón humano para el tratamiento de diversos trastornos? |
EP2732825B1 (en) | 2012-11-19 | 2015-07-01 | Invivogen | Conjugates of a TLR7 and/or TLR8 agonist and a TLR2 agonist |
ES2625023T3 (es) | 2012-11-20 | 2017-07-18 | Glaxosmithkline Llc | Compuestos novedosos |
RS56233B1 (sr) | 2012-11-20 | 2017-11-30 | Glaxosmithkline Llc | Nova jedinjenja |
US9550785B2 (en) | 2012-11-20 | 2017-01-24 | Glaxosmithkline Llc | Pyrrolopyrimidines as therapeutic agents for the treatment of diseases |
EP2769738B1 (en) | 2013-02-22 | 2016-07-20 | Invivogen | Conjugated TLR7 and/or TLR8 and TLR2 polycationic agonists |
KR20160124157A (ko) * | 2014-02-20 | 2016-10-26 | 글락소스미스클라인 인털렉츄얼 프로퍼티 (넘버 2) 리미티드 | 인간 인터페론의 유도인자로서의 피롤로[3,2]피리미딘 유도체 |
WO2015130584A2 (en) | 2014-02-25 | 2015-09-03 | Merck Sharp & Dohme Corp. | Lipid nanoparticle vaccine adjuvants and antigen delivery systems |
EP3160453A1 (en) | 2014-06-25 | 2017-05-03 | Selecta Biosciences, Inc. | Methods and compositions for treatment with synthetic nanocarriers and immune checkpoint inhibitors |
AU2015287773B2 (en) | 2014-07-11 | 2018-03-29 | Gilead Sciences, Inc. | Modulators of toll-like receptors for the treatment of HIV |
CN106715431A (zh) | 2014-09-16 | 2017-05-24 | 吉利德科学公司 | Toll样受体调节剂的固体形式 |
JP2017533925A (ja) * | 2014-11-13 | 2017-11-16 | グラクソスミスクライン バイオロジカルズ ソシエテ アノニム | アレルギー性疾患又は他の炎症状態の治療に有用なアデニン誘導体 |
WO2017205383A1 (en) * | 2016-05-23 | 2017-11-30 | University Of Iowa Research Foundation | Method of treating cystic fibrosis airway disease |
CN109476696B (zh) * | 2016-06-02 | 2022-06-10 | 细胞基因公司 | 动物及人抗锥虫和抗利什曼原虫剂 |
CA3057813A1 (en) | 2017-03-29 | 2018-10-04 | Sumitomo Dainippon Pharma Co., Ltd. | Vaccine adjuvant formulation |
CN108948016B (zh) * | 2017-05-19 | 2021-02-26 | 江苏恒瑞医药股份有限公司 | 嘌呤酮类衍生物、其制备方法及其在医药上的应用 |
CN111587114A (zh) | 2017-11-14 | 2020-08-25 | 儿童医学中心公司 | 用于调节人免疫应答的咪唑并嘧啶的用途 |
JP7304855B2 (ja) | 2017-11-14 | 2023-07-07 | ザ チルドレンズ メディカル センター コーポレーション | 新規イミダゾピリミジン化合物およびそれらの使用 |
US11812433B2 (en) | 2017-11-17 | 2023-11-07 | Ntt Docomo, Inc. | User terminal and radio communication method |
WO2019124500A1 (ja) | 2017-12-21 | 2019-06-27 | 大日本住友製薬株式会社 | Tlr7アゴニストを含む併用薬 |
WO2020022272A1 (ja) | 2018-07-23 | 2020-01-30 | 公益財団法人ヒューマンサイエンス振興財団 | インフルエンザワクチンを含む組成物 |
US11486970B1 (en) | 2019-02-11 | 2022-11-01 | Innovusion, Inc. | Multiple beam generation from a single source beam for use with a LiDAR system |
CA3138461A1 (en) * | 2019-05-23 | 2020-11-26 | Helene Bazin-Lee | Vaccine adjuvants based on tlr receptor ligands |
WO2020263660A1 (en) * | 2019-06-24 | 2020-12-30 | Merck Sharp & Dohme Corp. | Process for the preparation of 2-fluoroadenine |
CN110772523B (zh) * | 2019-11-07 | 2020-06-26 | 黑龙江中医药大学 | 一种用于防治肾病的药物组合物 |
WO2024028794A1 (en) | 2022-08-02 | 2024-02-08 | Temple Therapeutics BV | Methods for treating endometrial and ovarian hyperproliferative disorders |
Family Cites Families (117)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB427857A (en) | 1934-08-02 | 1935-05-01 | Newsum Sons & Company Ltd H | A new or improved system of construction for skeleton structures, particularly vehicle body frames and door frames |
TW530047B (en) | 1994-06-08 | 2003-05-01 | Pfizer | Corticotropin releasing factor antagonists |
US6403599B1 (en) | 1995-11-08 | 2002-06-11 | Pfizer Inc | Corticotropin releasing factor antagonists |
US7067664B1 (en) | 1995-06-06 | 2006-06-27 | Pfizer Inc. | Corticotropin releasing factor antagonists |
AU3176297A (en) | 1996-06-25 | 1998-01-14 | Novartis Ag | Substituted 7-amino-pyrrolo{3,2-d}pyrimidines and the use thereof |
US6126919A (en) | 1997-02-07 | 2000-10-03 | 3M Innovative Properties Company | Biocompatible compounds for pharmaceutical drug delivery systems |
US5985848A (en) | 1997-10-14 | 1999-11-16 | Albert Einstein College Of Medicine Of Yeshiva University | Inhibitors of nucleoside metabolism |
TW572758B (en) | 1997-12-22 | 2004-01-21 | Sumitomo Pharma | Type 2 helper T cell-selective immune response inhibitors comprising purine derivatives |
US6187777B1 (en) | 1998-02-06 | 2001-02-13 | Amgen Inc. | Compounds and methods which modulate feeding behavior and related diseases |
US6232320B1 (en) | 1998-06-04 | 2001-05-15 | Abbott Laboratories | Cell adhesion-inhibiting antiinflammatory compounds |
CZ27399A3 (cs) | 1999-01-26 | 2000-08-16 | Ústav Experimentální Botaniky Av Čr | Substituované dusíkaté heterocyklické deriváty, způsob jejich přípravy, tyto deriváty pro použití jako léčiva, farmaceutická kompozice a kombinovaný farmaceutický přípravek tyto deriváty obsahující a použití těchto derivátů pro výrobu léčiv |
EP1065213A3 (en) | 1999-07-02 | 2003-11-05 | Japan Tobacco Inc. | HCV polymerase suitable for crystal structure analysis and method for using the enzyme |
SK13752001A3 (sk) | 1999-12-27 | 2002-07-02 | Japan Tobacco, Inc. | Zlúčeniny s fúzovanými kruhmi a ich použitie ako liečiv |
AU3540101A (en) | 2000-01-07 | 2001-07-16 | Universitaire Instelling Antwerpen | Purine derivatives, process for their preparation and use thereof |
TW200505900A (en) | 2000-04-28 | 2005-02-16 | Acadia Pharm Inc | Muscarinic agonists |
US6448281B1 (en) | 2000-07-06 | 2002-09-10 | Boehringer Ingelheim (Canada) Ltd. | Viral polymerase inhibitors |
US6310224B1 (en) | 2001-01-19 | 2001-10-30 | Arco Chemical Technology, L.P. | Epoxidation catalyst and process |
CZ20032005A3 (en) | 2001-01-22 | 2004-04-14 | Merck & Co., Inc. | Nucleoside derivatives as inhibitors of RNA-dependent RNA viral polymerase |
KR20030093248A (ko) | 2001-03-19 | 2003-12-06 | 오노 야꾸힝 고교 가부시키가이샤 | 트리아자스피로[5.5]운데칸 유도체를 유효성분으로서함유하는 약제 |
GB0114286D0 (en) * | 2001-06-12 | 2001-08-01 | Hoffmann La Roche | Nucleoside Derivatives |
AR035543A1 (es) | 2001-06-26 | 2004-06-16 | Japan Tobacco Inc | Agente terapeutico para la hepatitis c que comprende un compuesto de anillo condensado, compuesto de anillo condensado, composicion farmaceutica que lo comprende, compuestos de benzimidazol, tiazol y bifenilo utiles como intermediarios para producir dichos compuestos, uso del compuesto de anillo con |
ATE541246T1 (de) | 2001-06-29 | 2012-01-15 | Maruman Products Co Ltd | Funkarmbanduhr |
CA2448737C (en) | 2001-07-20 | 2010-06-01 | Boehringer Ingelheim (Canada) Ltd. | Viral polymerase inhibitors |
TW200301251A (en) | 2001-12-20 | 2003-07-01 | Wyeth Corp | Azaindolylalkylamine derivatives as 5-hydroxytryptamine-6 ligands |
EP1348707B1 (en) | 2002-03-28 | 2010-08-25 | Ustav Experimentalni Botaniky AV CR, v.v.i. (Institute of Experimental Botany Academy of Sciences of the Czech Republic, PRO) | Pyrazolo[4,3-d]pyrimidines, processes for their preparation and methods for therapy |
CA2481502A1 (en) | 2002-04-04 | 2003-10-16 | Achillion Pharmaceuticals, Inc. | Hcv antiviral and cytotoxicity drug screening assay |
CN1653077A (zh) | 2002-05-06 | 2005-08-10 | 健亚生物科技公司 | 治疗c型肝炎病毒感染的核苷衍生物 |
DOP2003000641A (es) | 2002-05-10 | 2003-11-15 | Pfizer | Inhibidores de las arn polimerasa dependiente de arn del virus de las hepatitis c y composiciones y tratamiento que los usan |
US6713241B2 (en) | 2002-08-09 | 2004-03-30 | Eastman Kodak Company | Thermally developable emulsions and imaging materials containing binder mixture |
RU2330042C2 (ru) | 2002-08-21 | 2008-07-27 | Альберт Эйнштейн Колледж Оф Медсин Оф Йешива Юниверсити | Ингибиторы нуклеозидфосфорилаз и нуклеозидаз |
ES2387388T3 (es) | 2002-09-27 | 2012-09-21 | Dainippon Sumitomo Pharma Co., Ltd. | Compuesto de adenina y uso del mismo |
AR041816A1 (es) | 2002-10-24 | 2005-06-01 | Glaxo Group Ltd | Compuesto de acil-pirrolidina, su uso para preparar una composicion farmaceutica, composicion farmaceutica que lo comprende y procedimiento para prepararlo |
US7569579B2 (en) | 2002-12-13 | 2009-08-04 | Smithkline Beecham Corporation | Cyclopropyl compounds as ccr5 antagonists |
JP2006511554A (ja) | 2002-12-13 | 2006-04-06 | スミスクライン ビーチャム コーポレーション | Ccr5アンタゴニストとしてのピペリジン誘導体 |
ATE410426T1 (de) | 2002-12-13 | 2008-10-15 | Smithkline Beecham Corp | Heterocyclische verbindungen alsccr5-antagonisten |
AU2003300952A1 (en) | 2002-12-13 | 2004-07-09 | Smithkline Beecham Corporation | Indane compounds as ccr5 antagonists |
JP2006514646A (ja) | 2002-12-13 | 2006-05-11 | スミスクライン ビーチャム コーポレーション | Ccr5アンタゴニストとしてのシクロヘキシル化合物類 |
US7271172B2 (en) | 2002-12-13 | 2007-09-18 | Smithkline Beecham Corporation | Pyrrolidine and azetidine compounds as CCR5 antagonists |
US7098231B2 (en) | 2003-01-22 | 2006-08-29 | Boehringer Ingelheim International Gmbh | Viral polymerase inhibitors |
US7223785B2 (en) | 2003-01-22 | 2007-05-29 | Boehringer Ingelheim International Gmbh | Viral polymerase inhibitors |
US7148226B2 (en) | 2003-02-21 | 2006-12-12 | Agouron Pharmaceuticals, Inc. | Inhibitors of hepatitis C virus RNA-dependent RNA polymerase, and compositions and treatments using the same |
EP1646614A4 (en) | 2003-07-01 | 2008-09-10 | Merck & Co Inc | OPHTHALMIC COMPOSITIONS FOR THE TREATMENT OF OCCULAR HYPERTONIA |
WO2005014543A1 (ja) | 2003-08-06 | 2005-02-17 | Japan Tobacco Inc. | 縮合環化合物及びそのhcvポリメラーゼ阻害剤としての利用 |
WO2005020892A2 (en) | 2003-08-08 | 2005-03-10 | Mitochroma Research, Inc. | Pharmaceutical compositions and methods for metabolic modulation |
GEP20084545B (en) | 2003-09-05 | 2008-11-25 | Anadys Pharmaceuticals Inc | Introducing tlr7 ligands and prodrugs thereof for the treatment of hepatitis c viral infection |
AR046172A1 (es) | 2003-10-03 | 2005-11-30 | 3M Innovative Properties Co | Pirazolopiridinas y sus analogos; composiciones farmaceuticas que los contienen y su uso en la inhibicion de la biosintesis de citocinas |
BRPI0416128B8 (pt) | 2003-11-03 | 2021-06-22 | Glaxo Group Ltd | dispositivo de dispensação de fluido |
ES2326082T3 (es) | 2003-12-01 | 2009-09-30 | L'oreal | Derivados de 4-5-diamino-n,n-dihidro-pirazol-3-ona condensados, utilizados para la tincion de fibras queratinicas. |
UA86962C2 (en) | 2004-02-20 | 2009-06-10 | Бёрингер Ингельхайм Интернациональ Гмбх | Viral polymerase inhibitors |
EP1728792A4 (en) * | 2004-03-26 | 2010-12-15 | Dainippon Sumitomo Pharma Co | 8-OXOADENINE COMPOUND |
BRPI0509258A8 (pt) * | 2004-03-26 | 2019-01-22 | Astrazeneca Ab | composto de 8-oxoadenina 9-substituída |
ATE471871T1 (de) | 2004-03-31 | 2010-07-15 | Yuyama Mfg Co Ltd | Tablettenzuführvorrichtung |
MXPA06011423A (es) | 2004-04-02 | 2007-01-23 | Osi Pharm Inc | Inhibidores de proteina cinasa heterobiciclica sustituida en el anillo 6,6-biciclico. |
WO2005105761A1 (en) | 2004-04-28 | 2005-11-10 | Arrow Therapeutics Limited | Morpholinylanilinoquinazo- line derivatives for use as antiviral agents |
MXPA06013250A (es) | 2004-05-14 | 2007-02-28 | Abbott Lab | Inhibidores de quinasa como agentes terapeuticos. |
US20060029642A1 (en) | 2004-08-03 | 2006-02-09 | Dusan Miljkovic | Methods and compositions for improved chromium complexes |
US7153848B2 (en) | 2004-08-09 | 2006-12-26 | Bristol-Myers Squibb Company | Inhibitors of HCV replication |
GEP20115305B (en) | 2004-08-18 | 2011-10-10 | Pfizer | Inhibitors of hepatitis c virus rna-dependent rna polymerase, compositions containing them and using the same for treatment |
US20060045885A1 (en) | 2004-08-27 | 2006-03-02 | Kedl Ross M | Method of eliciting an immune response against HIV |
GB0420719D0 (en) | 2004-09-17 | 2004-10-20 | Addex Pharmaceuticals Sa | Novel allosteric modulators |
GB0423673D0 (en) | 2004-10-25 | 2004-11-24 | Glaxo Group Ltd | Compounds |
MX2007013780A (es) * | 2005-05-04 | 2008-02-05 | Pfizer Ltd | Derivados 2 amido-6-amino-8-oxo purina como moduladores del receptor como tipo peaje (toll) para el tratamiento del cancer y las infecciones virales tal como la hepatitis c. |
EA200702445A1 (ru) | 2005-05-09 | 2008-04-28 | Ачиллион Фармасьютикалз, Инк. | Соединения тиазола и способы их применения |
NZ540160A (en) | 2005-05-20 | 2008-03-28 | Einstein Coll Med | Inhibitors of nucleoside phosphorylases |
AU2006272876A1 (en) | 2005-07-22 | 2007-02-01 | Sunesis Pharmaceuticals, Inc. | Pyrazolo pyrimidines useful as aurora kinase inhibitors |
EP1931352B1 (en) * | 2005-08-22 | 2016-04-13 | The Regents of The University of California | Tlr agonists |
US8003624B2 (en) | 2005-08-25 | 2011-08-23 | Schering Corporation | Functionally selective ALPHA2C adrenoreceptor agonists |
BRPI0615307A2 (pt) | 2005-08-25 | 2009-08-04 | Schering Corp | agonistas de adrenorreceptor alfa2c |
JP4584335B2 (ja) | 2005-09-02 | 2010-11-17 | ファイザー・インク | ヒドロキシ置換1h−イミダゾピリジンおよび方法 |
TW200801003A (en) * | 2005-09-16 | 2008-01-01 | Astrazeneca Ab | Novel compounds |
WO2007034917A1 (ja) * | 2005-09-22 | 2007-03-29 | Dainippon Sumitomo Pharma Co., Ltd. | 新規なアデニン化合物 |
WO2007034817A1 (ja) * | 2005-09-22 | 2007-03-29 | Dainippon Sumitomo Pharma Co., Ltd. | 新規アデニン化合物 |
US20080269240A1 (en) * | 2005-09-22 | 2008-10-30 | Dainippon Sumitomo Pharma Co., Ltd. a corporation of Japan | Novel Adenine Compound |
JPWO2007034916A1 (ja) * | 2005-09-22 | 2009-03-26 | 大日本住友製薬株式会社 | 新規アデニン化合物 |
JPWO2007034881A1 (ja) * | 2005-09-22 | 2009-03-26 | 大日本住友製薬株式会社 | 新規アデニン化合物 |
TW200745114A (en) * | 2005-09-22 | 2007-12-16 | Astrazeneca Ab | Novel compounds |
CN1947717B (zh) | 2005-10-14 | 2012-09-26 | 卓敏 | 选择性抑制腺苷酸环化酶1的化合物在制备用于治疗神经性疼痛和炎性疼痛的药物中的应用 |
AU2007216247A1 (en) | 2006-02-17 | 2007-08-23 | Pfizer Limited | 3 -deazapurine derivatives as TLR7 modulators |
US8349850B2 (en) | 2006-03-28 | 2013-01-08 | Atir Holding S.A. | Heterocyclic compounds and uses thereof in the treatment of sexual disorders |
GB0610666D0 (en) | 2006-05-30 | 2006-07-05 | Glaxo Group Ltd | Fluid dispenser |
CA2653941C (en) * | 2006-05-31 | 2013-01-08 | The Regents Of The University Of California | Substituted amino purine derivatives and uses thereof |
US20070282962A1 (en) | 2006-06-01 | 2007-12-06 | Microsoft Corporation | Auto-Subscribing to Syndication Feeds Using Contact Lists |
WO2008004948A1 (en) * | 2006-07-05 | 2008-01-10 | Astrazeneca Ab | 8-oxoadenine derivatives acting as modulators of tlr7 |
AU2007269557B2 (en) * | 2006-07-07 | 2013-11-07 | Gilead Sciences, Inc. | Modulators of toll-like receptor 7 |
TW200831105A (en) * | 2006-12-14 | 2008-08-01 | Astrazeneca Ab | Novel compounds |
TW200843779A (en) | 2007-02-19 | 2008-11-16 | Smithkline Beecham Corp | Compounds |
US8067413B2 (en) | 2007-03-19 | 2011-11-29 | Astrazeneca Ab | 9-substituted-8-oxo-adenine compounds as toll-like receptor (TLR7 ) modulators |
ATE530549T1 (de) * | 2007-03-19 | 2011-11-15 | Astrazeneca Ab | 9-substituierte 8-oxoadeninverbindungen als modulatoren des toll-like-receptor (tlr7) |
WO2008114819A1 (ja) * | 2007-03-20 | 2008-09-25 | Dainippon Sumitomo Pharma Co., Ltd. | 新規アデニン化合物 |
AR065784A1 (es) * | 2007-03-20 | 2009-07-01 | Dainippon Sumitomo Pharma Co | Derivados de 8-oxo adenina,medicamentos que los contienen y usos como agentes terapeuticos para enfermedades alergicas, antivirales o antibacterianas. |
US7928111B2 (en) | 2007-06-08 | 2011-04-19 | Senomyx, Inc. | Compounds including substituted thienopyrimidinone derivatives as ligands for modulating chemosensory receptors |
PT2170888E (pt) * | 2007-06-29 | 2015-08-21 | Gilead Sciences Inc | Purina derivados e sua utilização como moduladores de recetor de tipo toll 7 |
GB0715087D0 (en) | 2007-08-03 | 2007-09-12 | Summit Corp Plc | Drug combinations for the treatment of duchenne muscular dystrophy |
EP2187883A2 (en) | 2007-08-10 | 2010-05-26 | Genelabs Technologies, Inc. | Nitrogen containing bicyclic chemical entities for treating viral infections |
UY31531A1 (es) | 2007-12-17 | 2009-08-03 | Sales derivadas de 8-oxoadenina composiciones farmacéuticas que las contienen y su uso en terapia como moduladores de receptor tipo toll (tlr) | |
WO2009151910A2 (en) * | 2008-05-25 | 2009-12-17 | Wyeth | Combination product of receptor tyrosine kinase inhibitor and fatty acid synthase inhibitor for treating cancer |
US8946239B2 (en) | 2008-07-10 | 2015-02-03 | Duquesne University Of The Holy Spirit | Substituted pyrrolo, -furano, and cyclopentylpyrimidines having antimitotic and/or antitumor activity and methods of use thereof |
PT2320905T (pt) | 2008-08-11 | 2017-09-19 | Glaxosmithkline Llc | Novos derivados de adenina |
US8802684B2 (en) | 2008-08-11 | 2014-08-12 | Glaxosmithkline Llc | Adenine derivatives |
UA103195C2 (uk) | 2008-08-11 | 2013-09-25 | Глаксосмитклайн Ллк | Похідні пурину для застосування у лікуванні алергій, запальних та інфекційних захворювань |
WO2010018132A1 (en) | 2008-08-11 | 2010-02-18 | Smithkline Beecham Corporation | Compounds |
JP2011530562A (ja) | 2008-08-11 | 2011-12-22 | グラクソスミスクライン エルエルシー | アレルギー性、炎症性及び感染性疾患治療用のプリン誘導体 |
WO2010018130A1 (en) | 2008-08-11 | 2010-02-18 | Smithkline Beecham Corporation | Purine derivatives for use in the treatment of allergic, inflammatory and infectious diseases |
WO2010083725A1 (zh) | 2009-01-20 | 2010-07-29 | 山东轩竹医药科技有限公司 | 含有取代的含氮稠杂环的头孢菌素衍生物 |
EA023536B1 (ru) | 2009-08-07 | 2016-06-30 | Глаксосмитклайн Байолоджикалс Са | Производные оксоаденина, конъюгированные с фосфо- или фосфонолипидами |
CN102753553B (zh) | 2010-02-10 | 2016-03-30 | 葛兰素史密丝克莱恩有限责任公司 | 6-氨基-2-{[(1s)-1-甲基丁基]氧基}-9-[5-(1-哌啶基)-7,9-二氢-8h-嘌呤-8-酮马来酸盐 |
US8575340B2 (en) | 2010-02-10 | 2013-11-05 | Glaxosmithkline Llc | Purine derivatives and their pharmaceutical uses |
WO2012009258A2 (en) | 2010-07-13 | 2012-01-19 | Edward Roberts | Peptidomimetic galanin receptor modulators |
WO2012092552A1 (en) | 2010-12-30 | 2012-07-05 | Selecta Biosciences, Inc. | Synthetic nanocarriers with reactive groups that release biologically active agents |
USRE47009E1 (en) | 2011-02-01 | 2018-08-28 | The Children's Hospital Of Philadelphia | HDAC inhibitors and therapeutic methods using the same |
WO2012106522A2 (en) | 2011-02-04 | 2012-08-09 | Duquesne University Of The Holy Spirit | Bicyclic and tricyclic pyrimidine tyrosine kinase inhibitors with antitubulin activity and methods of treating a patient |
LT2734186T (lt) | 2011-07-22 | 2018-12-10 | Glaxosmithkline Llc | Kompozicija |
UY34987A (es) | 2012-08-24 | 2014-03-31 | Glaxosmithkline Llc | ?nuevos compuestos inductores del interferón humano para el tratamiento de diversos trastornos? |
US9550785B2 (en) | 2012-11-20 | 2017-01-24 | Glaxosmithkline Llc | Pyrrolopyrimidines as therapeutic agents for the treatment of diseases |
RS56233B1 (sr) | 2012-11-20 | 2017-11-30 | Glaxosmithkline Llc | Nova jedinjenja |
ES2625023T3 (es) | 2012-11-20 | 2017-07-18 | Glaxosmithkline Llc | Compuestos novedosos |
KR20160124157A (ko) | 2014-02-20 | 2016-10-26 | 글락소스미스클라인 인털렉츄얼 프로퍼티 (넘버 2) 리미티드 | 인간 인터페론의 유도인자로서의 피롤로[3,2]피리미딘 유도체 |
-
2009
- 2009-07-08 UA UAA201100703A patent/UA103195C2/uk unknown
- 2009-08-07 LT LTEP15170143.0T patent/LT3000813T/lt unknown
- 2009-08-07 EP EP09781606.0A patent/EP2324026B1/en active Active
- 2009-08-07 BR BRPI0917138A patent/BRPI0917138A2/pt not_active Application Discontinuation
- 2009-08-07 PL PL15170143T patent/PL3000813T3/pl unknown
- 2009-08-07 MX MX2011001666A patent/MX2011001666A/es active IP Right Grant
- 2009-08-07 NZ NZ602812A patent/NZ602812A/en not_active IP Right Cessation
- 2009-08-07 EP EP15170143.0A patent/EP3000813B1/en active Active
- 2009-08-07 DK DK09781606.0T patent/DK2324026T3/en active
- 2009-08-07 SI SI200931267T patent/SI2324026T1/sl unknown
- 2009-08-07 PE PE2011000155A patent/PE20110674A1/es active IP Right Grant
- 2009-08-07 SG SG2013055884A patent/SG192547A1/en unknown
- 2009-08-07 EP EP17205469.4A patent/EP3336089A1/en not_active Withdrawn
- 2009-08-07 RS RS20180242A patent/RS56984B1/sr unknown
- 2009-08-07 DK DK15170143.0T patent/DK3000813T3/da active
- 2009-08-07 MY MYPI2011000594A patent/MY162538A/en unknown
- 2009-08-07 PL PL09781606T patent/PL2324026T3/pl unknown
- 2009-08-07 CN CN200980141103.7A patent/CN102177159B/zh not_active Expired - Fee Related
- 2009-08-07 RS RS20150606A patent/RS54266B1/en unknown
- 2009-08-07 ME MEP-2015-138A patent/ME02274B/me unknown
- 2009-08-07 NZ NZ590782A patent/NZ590782A/xx not_active IP Right Cessation
- 2009-08-07 AU AU2009281197A patent/AU2009281197B2/en not_active Ceased
- 2009-08-07 US US12/537,392 patent/US8067426B2/en active Active
- 2009-08-07 NO NO15170143A patent/NO3000813T3/no unknown
- 2009-08-07 WO PCT/EP2009/060265 patent/WO2010018133A1/en active Application Filing
- 2009-08-07 HU HUE15170143A patent/HUE036570T2/hu unknown
- 2009-08-07 CN CN201410287455.6A patent/CN104098568B/zh not_active Expired - Fee Related
- 2009-08-07 CA CA2733749A patent/CA2733749C/en not_active Expired - Fee Related
- 2009-08-07 EA EA201100113A patent/EA020631B1/ru not_active IP Right Cessation
- 2009-08-07 TR TR2018/02648T patent/TR201802648T4/tr unknown
- 2009-08-07 US US13/058,470 patent/US8765772B2/en active Active
- 2009-08-07 SI SI200931799T patent/SI3000813T1/en unknown
- 2009-08-07 MX MX2012012018A patent/MX336345B/es unknown
- 2009-08-07 ES ES15170143.0T patent/ES2661671T3/es active Active
- 2009-08-07 ES ES09781606.0T patent/ES2549154T3/es active Active
- 2009-08-07 PT PT151701430T patent/PT3000813T/pt unknown
- 2009-08-07 PT PT97816060T patent/PT2324026E/pt unknown
- 2009-08-07 KR KR1020117005860A patent/KR101669939B1/ko active IP Right Grant
- 2009-08-07 HU HUE09781606A patent/HUE027637T2/en unknown
- 2009-08-07 JP JP2011522486A patent/JP5529867B2/ja not_active Expired - Fee Related
-
2011
- 2011-01-19 CO CO11005402A patent/CO6351791A2/es not_active Application Discontinuation
- 2011-01-20 IL IL210757A patent/IL210757A/en active IP Right Grant
- 2011-02-01 ZA ZA2011/00845A patent/ZA201100845B/en unknown
- 2011-02-08 DO DO2011000048A patent/DOP2011000048A/es unknown
- 2011-02-11 CL CL2011000301A patent/CL2011000301A1/es unknown
- 2011-03-03 CR CR20110116A patent/CR20110116A/es unknown
- 2011-03-08 MA MA33686A patent/MA32624B1/fr unknown
- 2011-10-13 US US13/272,956 patent/US9346806B2/en active Active
- 2011-11-10 HK HK11112171.3A patent/HK1157770A1/xx not_active IP Right Cessation
-
2014
- 2014-05-16 US US14/280,115 patent/US9233962B2/en not_active Expired - Fee Related
-
2015
- 2015-09-07 HR HRP20150938TT patent/HRP20150938T1/hr unknown
- 2015-09-22 SM SM201500224T patent/SMT201500224B/xx unknown
-
2016
- 2016-04-21 US US15/134,623 patent/US9877968B2/en active Active
- 2016-09-21 HK HK16111100.6A patent/HK1222857A1/zh not_active IP Right Cessation
-
2017
- 2017-12-19 US US15/846,475 patent/US10117873B2/en not_active Expired - Fee Related
-
2018
- 2018-02-02 HR HRP20180202TT patent/HRP20180202T1/hr unknown
- 2018-02-28 CY CY20181100258T patent/CY1119992T1/el unknown
- 2018-10-01 US US16/148,125 patent/US20190038631A1/en not_active Abandoned
- 2018-10-05 HK HK18112732.8A patent/HK1253532A1/zh unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CY1119992T1 (el) | Παραγωγα πουρινης για χρηση στη θεραπευτικη αγωγη αλλεργικων, φλεγμονωδων και λοιμωδων ασθενειων | |
EA201100114A1 (ru) | Производные пурина для применения в лечении аллергических, воспалительных и инфекционных заболеваний | |
CY1119368T1 (el) | Νεα παραγωγα αδενινης | |
CY1111281T1 (el) | Παραγωγα πουρινης ως ανοσοτροποποιητες | |
EA201590189A1 (ru) | Пиразолопиримидиновые соединения | |
CY1119557T1 (el) | Νεες ενωσεις | |
CY1122863T1 (el) | Φαρμακευτικη συνθεση που περιεχει γλυκοπυρρολικο και εναν αγωνιστη βητα2 αδρενοϋποδοχεα | |
CY1121188T1 (el) | Αμιδο-υποκατεστημενες ετεροκυκλικες ενωσεις χρησιμες ως διαμορφωτες των αποκρισεων il-12, il-23 και/η ifn-αλφα | |
CY1116791T1 (el) | 4-αρυλ-ν-φαινυλ-1,3,5-τριαζιν-αμινες που περιεχουν μια ομαδα σουλφοξιμινης | |
CY1119252T1 (el) | Νεα παραγωγα 1-βενζυλο-3 -υδροξυμεθυλινδαζολης και χρηση αυτων στη θεραπεια νοσων που βασιζονται στην εκφραση των cx3cr1 και ρ40 | |
CY1106894T1 (el) | Παραγωγα σουλφοναμιδιων για την αγωγη ασθενειων | |
CY1126109T1 (el) | Αναστολεις toy trpc6 | |
CY1109227T1 (el) | Παραγωγα της 5-φαινυλο-4-μεθυλο-θειαζολ-2-υλ-αμινης ως αναστολεις των ενζυμων κινασης της φωσφατιδυλινοσιτολης 3 (p13) για την θεραπεια των φλεγμονωδων ασθενειων των αεραγωγων | |
CY1116405T1 (el) | Ν1/ν2-λακταμικοι αναστολεις ακετυλο-coa καρβοξυλασης | |
EA201290631A1 (ru) | Малеат 6-амино-2-{[(1s)-1-метилбутил]окси}-9-[5-(1-пиперидинил)пентил]-7,9-дигидро-8н-пурин-8-она | |
CY1109656T1 (el) | Υποκατεστημενα παραγωγα μορφολινης και θειομορφολινης | |
CY1119108T1 (el) | Τηγμενα πυρρολοδικαρβοξαμιδια και η χρηση τους ως φαρμακευτικα προϊοντα | |
CY1119289T1 (el) | Παραγωγα 1,3-διυδρο-2η-βενζιμιδαζολ-2-ονης υποκατεστημενα με ετεροκυκλικους δακτυλιους ως αντι-ιικοι παραγοντες αναπνευστικου συγκυτιακου ιου | |
CY1108942T1 (el) | Παραγωγα 2-(1η-ινδολυλοσουλφανυλ)-αρυλαμινης δια χρησιν εις την θεραπειαν συναισθηματικων διαταραχων, πονου, adhd και αγχους ακρατειας ουρων | |
CY1121115T1 (el) | Σικλεσονιδη για τη θεραπεια της νοσου των αεραγωγων σε αλογα | |
CY1116844T1 (el) | Παραγωγα πουρινης για χρηση στη θεραπεια αλλεργικων, φλεγμονωδων και μολυσματικων ασθενειων | |
DE60203106D1 (de) | Azolylcarbynol-derivative von aryl (oder heteroaryl) zur behandlung von atemwegserkrankungen | |
AR074754A1 (es) | Derivados de purina-8-ona | |
CY1116091T1 (el) | Μηλεϊνικη 6-αμινο-2-{[(1s)-1-μεθυλβουτυλ]οξυ}-9-[5-(1-πιπεριδινυλ)πεντυλ]-7,9-διυδρο-8η-πουριν-8-ονη | |
CY1113406T1 (el) | Ενωσεις για την αγωγη της ηπατιτιδας c |